Carole Nuechterlein has headed the Roche Venture Fund since 2001.
Prior to her current position, Carole worked in the pharmaceutical/biotech industry as an attorney for ten years. She joined Roche from SangStat in Fremont, California, where she was General Counsel. She currently serves as a Director at Aligos Therapeutics, Arch Oncology, BCGT Acquisition Corp, CiVi Biopharma, Entrada Therapeutics, Maculogix, Millendo Therapeutics, Mission Therapeutics, Second Genome and Vivet Therapeutics, as well as a Board observer for Enliven Therapeutics. She was formerly a Director at Allakos and AveXis.
Carole has a BA from Valparaiso University and a JD from University of Michigan.
More information on the Roche Venture Fund can be found at: www.venturefund.roche.com